Meeting
2016 ASCO Annual Meeting
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
Authors
Yong Sang Hong
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Yong Sang Hong , Jeeyun Lee , Hye Sook Han , Soo Jung Lee , Jin-Soo Kim , Baek-Yeol Ryoo , Hyeong-Seok Lim , Dae Ho Lee , Kyu-Pyo Kim , Jeong Eun Kim , Se Hoon Park , Seung Tae Kim , Ki Hyeong Lee , Moon Ki Choi , Hyesun Han , Young su Noh , Yo Han Kim , Jahoon Kang , Jeewoong Son , Tae Won Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02405065
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2570)
DOI
10.1200/JCO.2016.34.15_suppl.2570
Abstract #
2570
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
First Author: John Sarantopoulos
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
First Author: Álvaro Lassaletta
Poster
2022 ASCO Annual Meeting
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
First Author: Patricia LoRusso